MY-004 is under clinical development by Createrna Science and Technology and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MY-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MY-004 overview
MY-004 is under development for the treatment of psoriasis, rheumatoid arthritis atopic dermatitis, IgA Nephropathy and systemic lupus erythematosus (SLE). It is administered through oral route. It acts by targeting the IRAK4 (Interleukin-1 receptor-associated kinase 4).
Createrna Science and Technology overview
Createrna Science and Technology (Createrna) is a drug research and development company. It focuses on developing inflammation, respiratory, renal system, and cardiovascular therapies. The company’s pipeline includes various drug candidates to treat rheumatoid arthritis, psoriasis, atopic dermatitis, inflammatory bowel disease, chronic pain, idiopathic pulmonary fibrosis, cough, paroxysmal nocturnal hemoglobinuria, IgA nephropathy, and hypertension. Createrna has developed a medical information platform to verify concepts in the early stages of projects. The company operates a research and development center and clinical medicine center in Wuhan and Shanghai, China. It was funded by Lilly Asia Venture and Vivo Capital. Createrna is headquartered in Wuhan, Hubei, China.
For a complete picture of MY-004’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
